Table 6.
Details of estimated immediate direct costs following gastroenterologist-initiated discontinuation.
| Episode | Services utilised | Unit price in GBP (£) | Total number of episodes | Total cumulative cost |
|---|---|---|---|---|
| Flare-up | Telephone call/clinic | 25 | 82 | 2050 |
| Corticosteroid therapy | Prescription | 9 | 21 | 189 |
| Outpatient attendance | 137 | 11 | 1507 | |
| Rescue therapy using biologics | Outpatient attendance | 137 | 58 | 7946 |
| Multi-disciplinary team meeting | 243 | 58 | 14,094 | |
| Cost of drug/s | ||||
| Infliximab* | 1200 | 66 infusions (11 pts) | 79,200 | |
| Adalimumab** | 140 | 754 injections (29 pts) | 105,560 | |
| Ustekinumab*** | 2150 | 24 injections (4 pts) | 51,600 | |
| Day-case unit for infusion (only for IV drugs) | 300 | 66 | 19,800 | |
| Hospitalisation | Inpatient stay | 727 | 7 | 5089 |
| Surgery including hospital stay | 3900 | 8 | 31,200 | |
| GRAND TOTAL | 266,635 |
*
Calculated for 12 months at 8 weekly infusions (presumed avg dose of 300 mg/dose).
**
Calculated for 12 months at fortnightly injections (presumed avg of 40 mg/dose).
***
Calculated for 12 months at 8 weekly injections (avg dose of 90 mg; induction dose excluded).